Iylon Precision Oncology shared on LinkedIn:
“Smarter Molecular Testing for Salivary Gland Cancers.
Salivary gland cancers are rare and include several tumor types with distinct genetic features. Researchers propose tailoring molecular testing according to the tumor’s appearance and aggressiveness rather than using the same approach for every patient.
Initial testing for markers such as MYB/MYBL1, HER2, androgen receptor, and NTRK could help identify potential treatment targets and determine whether broader genetic sequencing is needed.
This step-by-step strategy may reduce unnecessary testing, use resources more efficiently, and support more personalized treatment for patients with salivary gland cancers.
At Iylon Precision Oncology (www.iylon.com), we harness genetic insights to provide personalized, evidence-based recommendations, helping guide the right medicine, for the right patient, at the right dose, at the right time, and aimed at the right target.”
Other articles about Salivary Gland Cancer on OncoDaily.